When clinicians performed a transurethral resection of the bladder lesion, histopathological examination showed an infiltrative high-grade carcinoma arranged in irregular nests and cords within desmoplastic stroma. Immunohistochemistry told a decisive story: the tumor cells expressed CK20, GATA3, and p63, partially expressed CK7 and Uroplakin III, and were negative for PSA and NKX3.1. That combination is the classic immunophenotype of urothelial carcinoma, the malignancy that arises from the transitional epithelium of the urinary tract. GATA3 is a highly sensitive marker of urothelial differentiation in high-grade tumors, while NKX3.1 is considered a sensitive and specific marker of prostatic origin. The tumor was not a prostate cancer at all. It was bladder cancer that had crossed the bladder neck and invaded the prostate, and the normal PSA level had provided no protection against the misdiagnosis that nearly followed.

Two weeks after admission, the patient underwent radical cystectomy, ileal conduit urinary diversion, and pelvic lymph-node dissection. The postoperative pathology revealed a tumor measuring approximately 4.5 by 4.0 by 1.0 centimeters that had invaded the full thickness of the bladder wall and extended directly into the prostatic stroma and capsule. Fourteen pelvic lymph nodes were negative for carcinoma, but the distal prostatic urethral margin was positive, and the tumor showed both lymphovascular invasion and perineural invasion. The pathological stage was assigned as pT4aN0M0, a designation that reflects the direct, contiguous extension of the bladder primary into the prostatic parenchyma. In the AJCC TNM staging system, prostatic stromal invasion by bladder urothelial carcinoma is classified as pT4a disease, and it is regarded as an important pathological feature of aggressive tumor biology.

PD-L1 immunohistochemistry performed on the primary lesion showed a tumor proportion score below 1 percent and an immune-cell score below 1 percent, indicating low expression. HER2 was negative. Because no neoadjuvant systemic therapy had been given and the final pathology showed pT4a disease with a positive margin, a multidisciplinary discussion concluded that adjuvant systemic therapy was indicated. Current guideline-based options support adjuvant cisplatin-based combination chemotherapy for patients with pT3/4 and/or pN+ disease when no neoadjuvant systemic therapy has been administered, while adjuvant nivolumab is a recommended alternative for high-risk muscle-invasive urothelial carcinoma when cisplatin-based chemotherapy is not feasible or is declined. The planned regimen was gemcitabine at 1,000 milligrams per square meter on days 1 and 8 plus cisplatin at 70 milligrams per square meter on day 1, repeated every 21 days for up to four cycles.

What actually happened next exposes a gap between what oncology guidelines recommend and what patients can tolerate. The patient received only approximately one week of platinum-based chemotherapy plus immunotherapy before treatment was discontinued after renewed shared decision-making, driven by poor tolerance and substantial financial burden. The authors of the case report acknowledge that the inability to deliver complete perioperative or adjuvant systemic therapy is a major limitation of the case and an important context for interpreting what followed. Approximately three months after radical cystectomy, the patient developed low back pain and was evaluated in the oncology department.

Whole-body bone scintigraphy and SPECT/CT fusion imaging demonstrated multiple osteolytic bone metastases involving the L2 and L4 vertebrae and their posterior elements, the bilateral iliac bones, the left acetabular rim, and the right inferior pubic ramus. The distribution is striking: despite negative pelvic lymph nodes at the time of surgery, the cancer had already seeded the axial and pelvic skeleton within a quarter of a year. The authors suggest that occult micrometastases not detectable on routine preoperative imaging may already have been present at the time of cystectomy, and that lymphovascular invasion, perineural invasion, and a positive prostatic urethral margin together indicated highly aggressive tumor biology that routine staging had underestimated.

Soon after the diagnosis of bone metastases, the patient received denosumab at 120 milligrams by subcutaneous injection every 4 weeks to reduce the risk of skeletal-related events, combined with intensity-modulated radiotherapy to the vertebral metastatic lesions at a prescribed dose of 30 Gy in 10 fractions. The choice of denosumab is supported by a phase III randomized controlled trial showing that it was non-inferior to zoledronic acid in delaying skeletal-related events in patients with bone metastases from advanced solid tumors, with a lower incidence of renal toxicity. However, in patients with symptomatic bone metastases, antiresorptive therapy alone is often insufficient to control local pain and maintain skeletal stability, and palliative radiotherapy is usually required as part of comprehensive treatment, consistent with ASTRO evidence-based guidance indicating that palliative radiation can effectively relieve pain associated with bone metastases and help achieve local lesion control.

The deeper lesson of this case lies in the diagnostic pitfall that nearly derailed the workup. Bladder urothelial carcinoma involving the prostate can spread through three major pathways: prostatic urethral mucosal involvement, prostatic ductal involvement, and direct stromal invasion. Among these patterns, stromal invasion represents the most clinically significant form because it reflects tumor infiltration into the prostatic parenchyma and is associated with advanced pathological stage and poorer oncological outcomes. Retrospective analyses of patients with bladder cancer and prostatic involvement have shown that prostatic stromal invasion is closely associated with decreased cancer-specific and overall survival and represents an independent adverse prognostic indicator. Compared with mucosal or ductal involvement alone, prostatic stromal invasion is associated with a higher risk of local recurrence and distant metastasis, and the depth of prostatic involvement independently predicts poor overall survival. Prognosis is determined primarily by the presence of stromal invasion rather than by whether prostatic involvement is contiguous or non-contiguous.

Previous studies have shown that PSA is often normal or only mildly elevated when bladder-derived urothelial carcinoma involves the prostate, which means a normal serum PSA level cannot be used to exclude urothelial carcinoma involving the prostate. Secondary prostatic involvement by bladder urothelial carcinoma has been reported in approximately 12 to 40 percent of radical cystectomy specimens, while primary prostatic urothelial carcinoma is rare, accounting for only 1 to 4 percent of prostate malignancies. Because some high-grade prostatic adenocarcinomas may exhibit solid, nested, or pseudopapillary growth patterns that closely mimic urothelial carcinoma morphologically, particularly in tumors involving the bladder neck or prostatic urethra, careful correlation with immunohistochemical findings is required to establish the correct tumor origin. A single immunomarker is insufficient for reliably distinguishing between these two tumor types, and the combined use of urothelial markers such as GATA3, p63, and Uroplakin III alongside prostatic markers such as PSA and NKX3.1 provides higher diagnostic accuracy than any single marker alone.

From a molecular perspective, urothelial carcinoma is characterized by a highly heterogeneous genomic landscape involving alterations in pathways related to chromatin remodeling, DNA damage repair, cell-cycle regulation, and receptor tyrosine kinase signaling. Comprehensive genomic analyses have demonstrated that muscle-invasive bladder cancer frequently harbors alterations in TP53, RB1, ERCC2, FGFR3, PIK3CA, and ARID1A, which contribute to genomic instability, tumor progression, and biological heterogeneity. Recent molecular classification studies have divided muscle-invasive bladder cancer into distinct subtypes, including basal/squamous and luminal categories, which demonstrate different biological characteristics and prognostic implications. Although comprehensive genomic sequencing was not performed in this patient, the rapid postoperative metastatic progression and extensive pathological risk factors may indicate underlying molecular abnormalities associated with aggressive tumor behavior, and future genomic profiling may help clarify the mechanisms responsible for prostatic stromal invasion and early distant dissemination in this rare subgroup.

For patients with a normal serum PSA level but a mass at the bladder neck or prostatic region, clinicians should remain alert to the possibility of prostatic involvement by bladder-derived urothelial carcinoma, and a routine immunohistochemical panel including GATA3, CK7, CK20, p63, Uroplakin III, PSA, and NKX3.1 should be used early for differential diagnosis. Prostatic stromal invasion combined with lymphovascular invasion, perineural invasion, and a positive surgical margin may indicate highly aggressive disease and an increased risk of early distant metastasis, requiring more active postoperative risk assessment, systemic treatment decision-making, and close follow-up. When perioperative or adjuvant systemic therapy cannot be administered or completed, any deviation from the recommended treatment plan should be thoroughly documented, discussed with the patient, and taken into consideration when interpreting early recurrence. In this case, the early bone metastases are best interpreted as a consequence of both aggressive pathological risk factors and the incomplete delivery of systemic therapy, rather than as a novel diagnostic entity. The patient is currently continuing treatment and follow-up.

Subject of Research: Case report of bladder urothelial carcinoma with prostatic stromal invasion and early postoperative bone metastases

Article Title: Urothelial carcinoma of the bladder with prostatic stromal invasion and early postoperative bone metastases: a case report

Article References: Wang, C., Wang, M., & He, Y. (2026). Urothelial carcinoma of the bladder with prostatic stromal invasion and early postoperative bone metastases: a case report. Frontiers in Urology, 6, Article 1910163. https://doi.org/10.3389/fruro.2026.1910163

Image Credits: AI Generated

DOI: 10.3389/fruro.2026.1910163

Keywords: urothelial carcinoma, prostatic stromal invasion, bone metastases, immunohistochemistry, PSA, radical cystectomy, denosumab, case report, Urothelial, carcinoma, bladder, prostatic

The technical rigour applied to MRI staging in this study merits attention, because MRI-derived T stage has historically been criticised for interobserver variability. The investigators required that ambiguous or borderline findings of extracapsular extension and seminal vesicle invasion be resolved by consensus among three subspecialty-trained radiologists, with tumours defaulting to T2 classification unless definite extension was agreed. This conservative approach likely reduced false upstaging, which is important because overcalling T3 disease could artificially inflate the apparent association between T stage and nodal positivity. The use of a single 3 Tesla scanner with a standardised multiparametric protocol and a 32-channel pelvic phased-array coil also reduced equipment-related heterogeneity, a common confounder in multi-scanner imaging studies. Readers should bear in mind, however, that these safeguards reflect the controlled conditions of a single-centre study, and the strength of the reported associations may be somewhat more modest in settings where MRI quality, scanner field strength, and reporting expertise vary more widely.

The finding that T3b retained independent predictive value within the Gleason 4 + 3 subgroup, with an odds ratio of approximately 23.6, is particularly informative given ongoing debates about how best to categorise intermediate-risk disease. Gleason 4 + 3 tumours — in which the pattern 4 component predominates over pattern 3 — are widely regarded as carrying substantially higher metastatic potential than their 3 + 4 counterparts, and many guidelines now group them with high-risk disease for management purposes. That seminal vesicle invasion on MRI added prognostic information on top of grade in this subgroup suggests that local extent and histological aggressiveness are not redundant markers but complementary dimensions of risk. A tumour that is both architecturally aggressive on biopsy and locally invasive on imaging appears to represent a particularly dangerous phenotype, one in which the probability of occult nodal disease is high enough that PSMA PET/CT findings are likely to materially alter treatment planning, whether by expanding the radiation field, prompting extended pelvic lymph node dissection, or steering patients toward systemic therapy in combination with local treatment.

Equally noteworthy is the zero rate of PSMA-positive nodal disease among patients who simultaneously had PSA below 20 ng/mL, MRI-derived T2 disease or lower, and Gleason score below 8. This triad of favourable features — modest PSA, organ-confined disease on MRI, and biopsy grade below the high-risk threshold — defined a subgroup in which nodal metastases were entirely absent in this cohort of 152 men. Such a finding, if replicated in larger and more diverse populations, could support a more selective approach to PSMA PET/CT referral, reserving the scan for patients whose clinical and imaging profile suggests meaningful pre-test probability of nodal disease. The logic is straightforward: the value of any diagnostic test depends on the prevalence of the target condition in the population tested. When pre-test probability approaches zero, even a highly accurate test contributes little, and the resources consumed — scanner time, radiopharmaceutical production, specialist reporting — may be better directed elsewhere. Conversely, patients with T3b or T4 disease on MRI represent the opposite end of the spectrum, where the high pre-test probability of nodal involvement makes PSMA PET/CT most informative.

The model’s discrimination, expressed as an area under the receiver operating characteristic curve of 0.863, indicates good but not perfect ability to separate patients with and without nodal disease. For context, an AUC of 0.5 corresponds to chance performance, values above 0.8 are generally considered acceptable for clinical prediction models, and values approaching 0.9 or higher are rare in medicine. The additional reporting of calibration plots and decision curve analysis reflects contemporary standards in prediction model research. Calibration plots assess whether predicted probabilities match observed frequencies across the risk spectrum — a model that systematically overestimates or underestimates risk can mislead even if its ranking of patients is accurate. Decision curve analysis goes further by quantifying net benefit across a range of threshold probabilities, effectively asking whether acting on the model’s predictions would lead to better decisions than default strategies such as treating all patients or treating none. The demonstration of clinical net benefit suggests the model could function as a practical triage instrument rather than merely a statistical exercise.

Several limitations inherent to the study design warrant consideration when interpreting these results. The retrospective, single-centre nature of the cohort means that referral patterns, imaging protocols, and reporting practices reflect one institution’s approach, and the 152 patients analysed were drawn from a larger pool of 199 staging scans after exclusions for incomplete records. Selection bias cannot be excluded: patients who underwent both MRI and PSMA PET/CT before treatment may differ systematically from those who did not. Furthermore, the definition of high-risk disease — PSA of at least 20 ng/mL, Gleason score of at least 8, or clinical stage of at least T3 — means the findings apply specifically to this population and cannot be extrapolated to men with lower-risk disease, in whom nodal metastases are rare and PSMA PET/CT yield is correspondingly low. The observation that some patients clinically staged as cT3 on digital rectal examination were downstaged to T2 or lower on MRI highlights the well-documented tendency of digital rectal examination to overestimate local extent, and it underscores why imaging-based staging has largely supplanted clinical examination for T-stage assignment in modern practice.

The biological rationale connecting local tumour extent to nodal spread is worth articulating. Prostate cancer spreads to lymph nodes through predictable lymphatic drainage pathways, and the probability of nodal metastasis correlates with tumour volume, grade, and the extent of local invasion. As tumour grows beyond the capsule and into adjacent structures, it encounters a richer network of lymphatic and vascular channels, increasing the opportunity for tumour cells to disseminate. Seminal vesicle invasion, in particular, has been associated with micrometastatic disease in pelvic nodes across decades of surgical-pathological studies, and the present study extends this association into the era of molecular imaging, where PSMA-targeted radiotracers can detect nodal deposits far smaller than the size thresholds that limited conventional CT and MRI. The convergence of an anatomical marker of local aggressiveness with a molecular imaging marker of metastatic disease provides a coherent picture of tumour behaviour that spans both local and systemic dimensions.

From a health systems perspective, the study’s framing around resource utilisation is timely. PSMA PET/CT has been incorporated into guidelines for the initial staging of high-risk prostate cancer in many jurisdictions, but scanner availability, radiopharmaceutical supply chains, and trained personnel remain constrained in numerous health systems, particularly outside major academic centres. A validated pre-test risk stratification tool built from variables already available at the time of referral — MRI stage, PSA, and biopsy grade — could allow centres to prioritise scans for patients most likely to benefit, while deferring or omitting imaging in patients with very low predicted probability of nodal disease. The authors’ decision to analyse Gleason 3 + 4 and 4 + 3 subgroups separately, rather than collapsing all Gleason 7 disease into a single category, reflects growing recognition that these patterns differ meaningfully in metastatic potential, and it provides clinicians with more granular guidance than a binary intermediate-risk label would allow.

Finally, the findings sit within a broader trajectory in prostate cancer imaging. PSMA-targeted agents have transformed not only staging but also the detection of recurrence, the selection of patients for radioligand therapy, and the planning of salvage treatment after local therapy failure. As molecular imaging becomes more accessible, questions shift from whether to scan toward whom to scan and when. Studies that identify simple, reproducible predictors of scan positivity — such as MRI-derived T stage — contribute to that evolving calculus. Future work will need to validate these associations in external cohorts, examine whether quantitative MRI features such as lesion volume or radiomic signatures add predictive value beyond categorical T stage, and determine whether risk-stratified scanning strategies improve outcomes without delaying the detection of genuinely nodal-positive disease. For now, the message for clinicians is that the MRI report, often treated primarily as a roadmap for biopsy and local treatment, also carries actionable information about the likelihood that a staging PSMA PET/CT will reveal nodal involvement — information that can be used to sequence investigations, counsel patients, and allocate imaging resources more rationally.

Subject of Research: MRI-derived T stage predicts nodal positivity on PSMA PET/CT in high-risk primary prostate cancer

Article Title: MRI-derived T stage predicts nodal positivity on PSMA PET/CT in high-risk primary prostate cancer

Article References: Courtney, M., Whiriskey, R., Johnston, C., & Sheehy, N. (2026). MRI-derived T stage predicts nodal positivity on PSMA PET/CT in high-risk primary prostate cancer. Frontiers in Nuclear Medicine, 6, Article 1854064. https://doi.org/10.3389/fnume.2026.1854064

Image Credits: AI Generated

DOI: 10.3389/fnume.2026.1854064

Keywords: prostate cancer, MRI, PSMA PET/CT, nodal metastasis, T stage, risk stratification, Gleason score, PSA, nuclear medicine, predictive model, MRI-derived, stage

The study was conducted as a cross-sectional analysis of men with histologically confirmed prostate cancer enrolled in two prospective registries: the International Registry for Men with Advanced Cancer (IRONMAN) and the African Cancer Genomic Registry (ACGR). Participants were recruited at two tertiary hospitals in Nairobi—Kenyatta National Hospital, a national public referral center, and MP Shah Hospital, a private tertiary facility. The sample size was calculated using Cochran’s formula, with a minimum required number of 162 patients based on a 95% confidence interval, a 5% margin of error, and an estimated population proportion of 0.88 representing patients presenting with advanced disease in Kenya.

Eligible participants were men aged 40 years or older with histologically confirmed prostate adenocarcinoma. The IRONMAN registry enrolled patients with locally advanced and metastatic prostate cancer, while the ACGR registry enrolled all patients with prostate cancer irrespective of stage. Patients included in the study from both registries were enrolled once to avoid potential overlap and duplication. Tumour stage was derived from clinical records and categorized as localized disease (T1-2, N0, M0) or advanced disease (T3-4 irrespective of N and M stage). PSA level at diagnosis was grouped into clinically meaningful, data-driven categories: ≤10, 11–20, 21–50, and >50 ng/mL. Gleason scores were obtained from diagnostic pathology reports and summarized according to individual WHO/ISUP Grade Groups.

Of the 170 men included in the stage-stratified analysis, only 26 (15.3%) presented with localized disease, while 144 (84.7%) had locally advanced or metastatic disease at diagnosis. The majority of patients were 70 years and older, and 85.9% (n=146) were recruited from the public hospital. More than half of the cohort (54.1%, n=92) had PSA values above 50 ng/mL, and WHO/ISUP grade group 5 dominated the histological patterns at 49.4%. These figures align with multi-country analyses documenting advanced-stage presentation among approximately 78%–85% of men with prostate cancer across sub-Saharan Africa.

PSA levels exhibited a strong, progressive gradient across tumour stages. Men with localized disease were predominantly concentrated within the lower PSA ranges, particularly below 20 ng/mL. As PSA levels increased, the distribution shifted progressively toward advanced-stage presentation. Men with PSA values between 21 and 50 ng/mL were already more likely to present with advanced disease than with localized disease. This trend became even more pronounced at higher thresholds: among men with PSA values over 50 ng/mL, 81 out of 92 (88%) had advanced disease at diagnosis.

Multivariable logistic regression analysis confirmed these associations. Compared with men with PSA ≤10 ng/mL, those with PSA levels of 11–20 ng/mL had significantly higher odds of advanced-stage disease (AOR=9.61, 95% CI: 1.61–57.26; p=0.013). Similarly, PSA levels >50 ng/mL were associated with significantly higher odds of advanced-stage disease (AOR=9.26, 95% CI: 2.12–40.34; p=0.003). Although men with PSA levels of 21–50 ng/mL also had higher odds of advanced-stage disease, the association did not reach statistical significance (AOR=3.99, 95% CI: 0.79–19.97; p=0.093). In a separate analysis treating PSA category as an ordinal variable, each increase in PSA category was associated with 59% higher odds of advanced-stage disease after adjustment for age (AOR=1.59, 95% CI: 1.05–2.41; p=0.029). Age was not independently associated with advanced-stage disease (AOR=1.00, 95% CI: 0.94–1.06; p=0.956). The authors caution that the wide confidence intervals around the category-specific estimates indicate considerable uncertainty and warrant cautious interpretation.

ISUP grade groups demonstrated a parallel association with tumour stage. Among the 168 men with available grade groups and stage data, 25 (15%) had localized disease, while 143 (85%) had advanced disease. Lower-grade tumours were more frequently observed among men with localized disease, whereas higher-grade tumours predominated among men with advanced-stage cancer. Notably, the ISUP grade 3 pattern was strongly associated with advanced disease, with 28 of 34 cases (82.4%) occurring among men with advanced-stage tumours. High-grade tumours (WHO/ISUP grade groups 4 and 5) constituted the majority of advanced-stage cases at 54.7%. Advanced disease predominated across all grade groups, ranging from 82.4% among patients with WHO/ISUP grade 3 disease to 86.9% among those with grade 5 disease. However, there was no statistically significant association between ISUP grade group and disease stage at diagnosis (Pearson χ²(1)=0.39, p=0.53), and in the multivariable analysis, advanced-stage disease was associated with 31% higher adjusted odds of having a higher grade group, an association that was not statistically significant (OR=1.31; 95% CI: 0.55–3.14; p=0.543).

Interestingly, each one-category increase in PSA was associated with 44% higher odds of having a higher ISUP grade after adjustment for age (OR=1.44; 95% CI: 1.02–2.04; p=0.040). Compared with men with PSA ≤10 ng/mL, PSA >50 ng/mL had 3.23 times the odds of high-grade group, although this did not reach statistical significance (95% CI: 0.79–13.09, p=0.101). Age was not significantly associated with the grade group category (AOR 1.01; 95% CI 0.97–1.06; p=0.682). Taken together, the PSA and ISUP grade distributions reveal a consistent clinicopathological profile: men diagnosed with localized disease represented a minority and were largely characterized by lower PSA values and lower-grade tumours, while advanced-stage disease predominated and was associated with markedly elevated PSA levels and a higher-grade histological pattern.

The authors suggest that both late diagnosis and aggressive tumour biology contribute to the predominance of advanced-stage prostate cancer in this cohort. Beyond health system constraints, emerging evidence points to biological and genetic factors that may contribute to the aggressive clinicopathological profile of prostate cancer among men of African ancestry, including ancestry-associated differences in tumour behavior, disease aggressiveness, and PSA-related risk stratification. However, the authors note that this relationship cannot be concluded from the present study due to the absence of molecular and genetic data. An additional observation was that advanced-stage disease predominated across all age categories, including men younger than 60 years, suggesting that delayed diagnosis is not restricted to a particular demographic but likely reflects broader challenges within the prostate cancer care pathway, including delayed health-seeking behavior, limited access to early diagnostic evaluation, and barriers to timely referral and specialist care.

A central, clinically actionable finding is that the strong association between PSA level and tumour stage supports the continued clinical utility of PSA as a clinical marker in resource-limited settings. The authors suggest that PSA values, particularly those above 50–100 ng/mL, may have potential utility as a pragmatic indicator for prioritizing expedited urological referral and staging at primary and secondary care levels, especially where specialist evaluation is not immediately accessible. However, given the cross-sectional nature of the study, these findings do not establish a referral threshold, and prospective studies would be required to validate the clinical utility of such PSA-based triage. The study has two main limitations: recruitment was primarily conducted at tertiary referral hospitals, which may preferentially capture patients with more advanced or complex disease and limit generalizability, and the cross-sectional design limits assessment of temporal relationships and precludes causal inference. Nevertheless, the combination of markedly elevated PSA, high-grade histology, and advanced-stage presentation highlights the need for earlier diagnosis and more efficient referral pathways in Kenya. Strengthening early detection, public awareness, and context-appropriate referral pathways may help reduce advanced-stage presentation and improve prostate cancer outcomes. Future research should explore the development and validation of pragmatic, data-driven approaches to prostate cancer risk assessment, referral, and early detection, and evaluate their feasibility and effectiveness within Kenyan and other sub-Saharan African healthcare settings.

Subject of Research: Prostate cancer in Kenya: registry analysis of PSA, stage, and ISUP grade at diagnosis

Article Title: Advanced stage at diagnosis and aggressive histology dominate prostate cancer presentation in Kenya: a registry analysis

Article References: Waihenya, C., Ojuka, D. K., Ragin, C., Zeigler-Johnson, C., Mbugua, R. W., & Thumbi, S. M. (2026). Advanced stage at diagnosis and aggressive histology dominate prostate cancer presentation in Kenya: a registry analysis. Frontiers in Cancer Control and Society, 4, Article 1946844. https://doi.org/10.3389/fcacs.2026.1946844

Image Credits: AI Generated

DOI: 10.3389/fcacs.2026.1946844

Keywords: prostate cancer, Kenya, PSA, WHO/ISUP grade groups, early detection, health systems, IRONMAN registry, ACGR, sub-Saharan Africa, cancer control, Advanced, stage

To understand why this matters, it helps to look at the diagnostic dilemma that has haunted prostate cancer medicine for decades. PSA is a protein produced by the prostate, and elevated levels can signal cancer, but they can also signal benign enlargement or inflammation. When a man’s PSA falls in the diagnostic gray zone of 4 to 10 nanograms per milliliter, clinicians face genuine uncertainty: the majority of these men do not have clinically significant cancer, yet the current pathway often sends many of them toward magnetic resonance imaging and, if the scan looks suspicious, toward needle biopsy. Biopsies are invasive, uncomfortable, carry a risk of bleeding and infection, and impose substantial costs on health systems. Every unnecessary biopsy avoided is a small victory for both patients and budgets.

The Prostate Health Index was designed specifically to sharpen this gray zone. It is a mathematical combination of three different forms of PSA, including a precursor form called p2PSA, yielding a single score that better discriminates aggressive cancer from benign conditions. In the pathway modeled by the Chinese team, men with PSA between 4 and 10 ng/mL would first receive a PHI test. Only those whose PHI exceeded a chosen cutoff would proceed to MRI, and only those with a sufficiently suspicious MRI result, graded PI-RADS 3 or higher on the standard Prostate Imaging Reporting and Data System, would undergo biopsy. This creates a layered funnel, with each filter designed to spare men without clinically significant disease from the more invasive and expensive steps downstream.

The study’s engine was a Markov microsimulation model, a technique that simulates the medical journey of individual hypothetical patients year by year as they move between health states such as healthy, screened, diagnosed, treated, and deceased. Microsimulation is particularly well suited to screening questions because it can track heterogeneity across a population: different men develop cancer at different rates, progress at different speeds, and respond differently to detection and treatment. By comparing two strategies head to head, the standard PSA pathway versus the PHI-augmented pathway, the researchers could tally up costs, quality-adjusted life years (QALYs), biopsies performed, cancers missed, and deaths over a lifetime horizon.

The headline results come from the base-case comparison: a PHI strategy that begins screening at age 50, repeats every two years, and uses a PHI cutoff of 35. Compared with the PSA strategy, this configuration reduced diagnostic costs by $643,398, a 30.1 percent saving, and reduced total costs by $1,115,276, or 6.4 percent, per 10,000 men screened. Most dramatically, it avoided 1,815 unnecessary biopsies, a 62.9 percent reduction. The trade-offs were real but modest: the PHI strategy produced 32 fewer QALYs, missed 6 additional cases of clinically significant prostate cancer, and resulted in 8 additional deaths per 10,000 men. The incremental cost-utility ratio, the extra cost per QALY gained by one strategy over another, came out at $34,852 per QALY, a figure the authors describe as favorable in the Chinese economic context.

That last number deserves unpacking, because it is the hinge on which the entire cost-effectiveness argument turns. Health economists typically judge a intervention’s value by comparing its cost per QALY against a willingness-to-pay threshold, often anchored to a country’s gross domestic product per capita. In China, interventions costing roughly one to three times GDP per capita per QALY are frequently considered good value. At $34,852 per QALY, the PHI strategy sits in a range that most health systems, including China’s rapidly expanding network of public health insurance schemes, could plausibly justify, especially given the enormous downstream savings from avoided biopsies and avoided imaging.

But the study did not stop at a single comparison. One of its most valuable contributions is a systematic exploration of how the three key dial settings, the age at which screening begins, the interval between screening rounds, and the PHI cutoff value, reshape the economics. The findings follow an intuitive logic. Starting screening at older ages, lengthening the intervals between rounds, or raising the PHI cutoff all push costs down and further reduce unnecessary biopsies. The price of that frugality, however, is a rise in missed diagnoses of clinically significant cancer, more deaths, and a loss of health utility. Screening too rarely or too late means cancers that would have been caught early instead progress undetected, and some men pay with their lives.

Within the secondary analyses, two configurations emerged as particularly attractive. Among the scenarios varying screening start age and interval, initiating screening at age 50 with a four-year interval showed favorable cost-effectiveness. Among the cutoff scenarios, a PHI cutoff of 35 performed best. In other words, the sweet spot is not the most aggressive screening schedule but a moderately intensive one: begin at 50, screen every four years rather than every two, and use a cutoff of 35 to decide who advances to MRI. This combination captures most of the biopsy-sparing and cost-saving benefits while keeping the losses in QALYs and the excess cancer deaths to a level the model judges acceptable.

The implications for Chinese health policy are considerable. China’s prostate cancer incidence has been climbing as the population ages and Westernized lifestyles spread, yet the country has no unified national prostate screening program comparable to organized screening efforts for cervical or breast cancer. Opportunistic PSA testing, where it happens at all, generates exactly the kind of overdiagnosis and overtreatment cascade this study set out to quantify. A PHI-based pathway, deployed with the parameters identified here, offers a blueprint for a more disciplined system: fewer men funneled into MRI, far fewer subjected to biopsy, and health dollars freed up for other priorities. Because the analysis was built specifically on Chinese cost data and population characteristics, its conclusions carry more local weight than extrapolations from European or American models.

As with any modeling study, caveats apply. Microsimulation models are only as good as the inputs fed into them, including cancer incidence, test performance, treatment outcomes, and costs, and the authors performed sensitivity analyses to probe how robust their conclusions were to uncertainty in these parameters. Real-world implementation would also raise questions the model cannot fully answer, such as laboratory capacity for p2PSA testing, adherence to screening schedules, and equitable access across urban and rural populations. Still, the study represents a rigorous, locally grounded step toward evidence-based prostate cancer screening policy in China. Its central message is one that health systems worldwide are grappling with: the future of cancer screening lies not in testing more, but in testing smarter, using layered, cost-conscious pathways that reserve invasive procedures for the men who genuinely need them.

Subject of Research: Cost-effectiveness of the Prostate Health Index for prostate cancer screening in Chinese men

Article Title: Economic evaluation of prostate health index for prostate cancer screening and diagnostic pathway in Chinese men by varying screening initiation ages, intervals, and cutoffs

Article References: Yan, T., Su, Z., Zhang, W., Lin, Y., Li, S., Yao, Q., Chen, Z., Dong, Y., Zhou, C., Lei, X., Gong, C., & Zhu, C. (2026). Economic evaluation of prostate health index for prostate cancer screening and diagnostic pathway in Chinese men by varying screening initiation ages, intervals, and cutoffs. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15762-x

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15762-x

Keywords: prostate cancer, Prostate Health Index, PSA, cost-effectiveness, screening, Markov model, MRI, biopsy, QALY, China, health economics, diagnostic pathway

The research, led by Weibo Wang, Chengyang Tian, and Supeng Tai, with Jun Zhou and Guangyue Luo as corresponding authors, took advantage of a prospectively maintained database spanning two separate campuses of the same hospital system. The development cohort comprised 355 patients evaluated at the Jixi Road Campus, while 203 patients from the High-Tech Campus served as an entirely independent external validation cohort. This two-campus design matters because prediction models are notoriously prone to overfitting, performing brilliantly on the data used to build them and then collapsing when confronted with new patients. By holding out a geographically and administratively distinct patient population, the investigators subjected their model to one of the most demanding tests available in clinical prediction research: does it still work on people it has never seen?

Among the 355 development-cohort patients, 67, or 18.9 percent, were found to have bone metastasis. In the external validation cohort the figure was 48 of 203, or 23.6 percent. These substantial prevalence rates underscore why the question is clinically urgent: roughly one in five newly diagnosed men in these cohorts harbored skeletal disease, and identifying them accurately at the outset is essential for correct staging and treatment planning. The researchers began by examining five inflammatory-immune indices, all calculable from routine blood work: the neutrophil-to-lymphocyte ratio, the platelet-to-lymphocyte ratio, the lymphocyte-to-monocyte ratio, the systemic immune-inflammation index, and the systemic inflammation response index. These indices have attracted growing attention in oncology because they capture, in crude but reproducible form, the interplay between a patient’s immune system and the systemic inflammatory state that tumors both induce and exploit.

The statistical machinery behind the model was deliberately rigorous. Associations between each inflammatory-immune index and bone metastasis were tested in the development cohort using multivariable logistic regression, with restricted cubic splines employed to allow for nonlinear relationships rather than forcing the data into straight-line assumptions. Predictor selection then proceeded through a two-stage strategy: repeated least absolute shrinkage and selection operator regression, a penalized technique that shrinks unstable coefficients toward zero and is prized for its robustness against overfitting, followed by stepwise logistic regression to finalize the variable set. The result was a lean, four-variable model. The predictors that survived repeated selection were log-transformed prostate-specific antigen, clinical T stage, biopsy Grade Group as defined by the International Society of Urological Pathology, and the neutrophil-to-lymphocyte ratio.

Two of the five inflammatory indices earned their place in the final analysis on statistical grounds. The neutrophil-to-lymphocyte ratio, or NLR, and the systemic immune-inflammation index both remained associated with bone metastasis after full adjustment for other factors. Expressed per one-standard-deviation increase in the transformed index, the odds ratio for the NLR was 1.58, with a 95 percent confidence interval of 1.12 to 2.22, while the systemic immune-inflammation index carried an odds ratio of 1.44, with a confidence interval of 1.03 to 2.03. In plain terms, patients whose blood showed a higher relative abundance of neutrophils compared with lymphocytes were meaningfully more likely to have bone metastases, even after accounting for how advanced their tumors appeared by conventional measures. This fits a broader biological picture in which neutrophil-dominated inflammation can foster tumor progression and metastatic seeding, while lymphopenia may signal a blunted anti-tumor immune response.

How well did the model actually perform? In the development cohort it achieved an area under the receiver operating characteristic curve, or AUC, of 0.905, with a 95 percent confidence interval of 0.869 to 0.941. Because models built and evaluated on the same data tend to look better than they are, the team applied bootstrap resampling to obtain an optimism-corrected AUC of 0.898, with a confidence interval of 0.864 to 0.934, a negligible loss of performance. The decisive test came in the external validation cohort, where the AUC was 0.884, with a confidence interval of 0.828 to 0.941. An AUC near 0.9 represents strong discriminative ability, meaning the model separates patients with bone metastasis from those without it with high fidelity. Calibration plots, which assess whether predicted probabilities match observed frequencies, and the Brier score, which penalizes both discrimination and calibration errors, remained consistent across internal and external validation, as did clinical net benefit measured by decision curve analysis.

One of the study’s most clinically relevant findings concerns the incremental value of the blood-based marker. Clinicopathological factors alone, without the NLR, produced an AUC of 0.887. Adding the neutrophil-to-lymphocyte ratio raised this to 0.905, a change in AUC of 0.018 with a P value of 0.034, indicating a statistically significant but modest improvement. The authors are appropriately measured on this point: NLR provided complementary information rather than a revolution. In practical terms, a cheap, universally available blood count parameter sharpened a model already built on PSA, tumor stage, and biopsy grade. That kind of incremental gain, verified on independent patients, is exactly what guideline committees look for when deciding whether to endorse a new tool, and it suggests the inflammatory marker carries genuine biological signal about metastatic behavior rather than statistical noise.

The clinical use case the researchers envision is decision support for imaging. Current practice often relies on PSA thresholds and risk categories to determine which newly diagnosed men should undergo bone scintigraphy or, increasingly, PSMA-targeted PET/CT, a modality that is more sensitive but far more expensive and less widely available. A validated model that outputs an individualized probability of bone metastasis could help clinicians and patients weigh the trade-off between missing occult skeletal disease and subjecting low-risk men to unnecessary imaging, radiation exposure, cost, and incidental findings. The model’s strong negative predictive potential in low-probability patients, reflected in its calibration and net-benefit performance, is particularly relevant for safely deferring imaging in men whose disease is very unlikely to have spread.

The study also stands out for its methodological transparency. The authors followed the TRIPOD+AI reporting checklist for prediction model research, obtained ethics approval from the Ethics Committee of the First Affiliated Hospital of Anhui Medical University with informed consent from all participants or their legal representatives, and conducted the work in accordance with the Declaration of Helsinki. The research was supported by funding from the Anhui Provincial Department of Education, the Health Committee of Anhui Province, and an provincial innovation team program for male genitourinary diseases. The team declares no competing interests, and the article is open access under a Creative Commons license.

Caveats remain, as they do for any retrospective, single-institution modeling study. The cohorts come from one Chinese hospital system, and generalization to populations with different ancestry, PSA screening patterns, and diagnostic pathways will require further external validation elsewhere. The model estimates probability rather than replacing imaging outright; a low predicted risk still warrants clinical judgment, and a high predicted risk still demands confirmatory scans. Nevertheless, the study demonstrates a template for how oncology prediction models should be built: prespecified inflammatory biomarkers, penalized and repeated variable selection, bootstrap internal validation, and, crucially, a genuinely independent external cohort. If future multi-center studies replicate these results, a four-variable calculation performed at the bedside, drawing on numbers already sitting in the medical record, could quietly change how newly diagnosed prostate cancer is staged, sparing low-risk men unnecessary scans while ensuring that men with silent skeletal disease are found and treated sooner.

Subject of Research: A diagnostic prediction model using inflammatory-immune indices and clinicopathological factors to identify bone metastasis in newly diagnosed prostate cancer

Article Title: Bone metastasis in newly diagnosed prostate cancer: development and external validation of a diagnostic prediction model based on inflammatory-immune indices and clinicopathological factors to support imaging decisions

Article References: Wang, W., Tian, C., Tai, S., Tao, J., Yan, J., Wang, S., Yang, L., Zhou, J., & Luo, G. (2026). Bone metastasis in newly diagnosed prostate cancer: development and external validation of a diagnostic prediction model based on inflammatory-immune indices and clinicopathological factors to support imaging decisions. BMC Cancer. https://doi.org/10.1186/s12885-026-17147-z

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17147-z

Keywords: prostate cancer, bone metastasis, neutrophil-to-lymphocyte ratio, prediction model, inflammatory-immune indices, PSA, external validation, diagnostic imaging, logistic regression, clinical decision support, BMC Cancer, cancer staging

The core problem lies in what clinicians call the diagnostic gray zone. Serum prostate-specific antigen (PSA), the workhorse of prostate cancer screening since the early 1990s, loses much of its discriminative power when values fall between 4 and 10 ng/mL, a range where benign prostatic hyperplasia and prostatitis routinely elevate the marker just as aggressively as tumors do. Multiparametric MRI, the other pillar of modern triage, has its own blind spot: lesions graded PI-RADS category 3, the equivocal middle of the Prostate Imaging Reporting and Data System, carry genuinely ambiguous cancer probability. In this gray zone, the overlap between malignant and benign disease drives a substantial number of unnecessary biopsies—procedures that carry real morbidity, from bleeding and infection to the psychological burden of waiting, and that frequently detect indolent cancers a patient might never have needed to know about.

The review’s authors, led by Zijie Nie and corresponding author Lingling Wu, organize the emerging solutions into three broad categories: liquid-based molecular biomarkers, advanced imaging modalities, and integrative frameworks that fuse multiple data streams. On the biomarker front, the most mature tools refine what PSA already tells us. The Prostate Health Index (PHI), a mathematical combination of total PSA, free PSA, and the precursor form p2PSA, has been validated across European and Asian populations, with recent large Chinese cohort data confirming its utility and newer derivatives such as PHI density—PHI divided by prostate volume—outperforming PSA density in equivocal MRI settings. The 4Kscore, a four-kallikrein blood panel, has shown its worth as a reflex test after elevated PSA; in the GÖTEBORG-2 screening trial it performed well as a second-line discriminator, and the ProScreen randomized trial demonstrated that combining PSA, the kallikrein panel, and MRI can streamline screening pathways.

Perhaps the most conceptually elegant of the refined PSA tools is IsoPSA, which abandons concentration measurement altogether. Instead of asking how much PSA is in the blood, IsoPSA interrogates the structural heterogeneity of the PSA protein itself—cancerous tissue produces subtly different molecular forms of the enzyme than benign tissue does. Prospective multicenter validation showed improved detection of both any cancer and high-grade disease compared with conventional total PSA, and notably, its performance characteristics are unaffected by 5-alpha reductase inhibitors and alpha-blockers, drugs that confound standard PSA interpretation. A recent study further reported that IsoPSA density improves risk stratification and biopsy decision-making for clinically significant cancer.

Urine-based tests exploit a different biological logic: tumor-derived molecular signatures can be captured non-invasively from prostatic fluid expressed during a digital rectal examination or simply from first-catch urine. SelectMDx, a two-gene mRNA test, has been validated in prospective multicenter studies of biopsy-naïve men and compared directly against mpMRI in diagnostic meta-analyses. MyProstateScore (MPS), built around the TMPRSS2:ERG fusion gene and PCA3, has demonstrated a robust ability to rule out clinically significant cancer, including in men with equivocal PI-RADS 3 lesions—precisely the population where the clinical need is greatest. Its successor, MyProstateScore 2.0, an 18-gene urine test validated in JAMA Oncology, extends this approach to high-grade cancer detection using first-catch urine without any prior examination, removing a logistical barrier to widespread use.

Exosome technology represents a further step along the liquid biopsy frontier. The ExoDx Prostate IntelliScore test analyzes gene expression in urinary exosomes—nanoscale vesicles shed by prostate tissue—to predict high-grade cancer at initial biopsy in men with PSA between 2 and 10 ng/mL, with clinical performance confirmed across three independent prospective studies. Beyond RNA, researchers are mining exosomes for proteins and metabolites: proteomic profiling of urinary large extracellular vesicles, chemical affinity capture of plasma extracellular vesicles for large-scale biomarker discovery, and metabolomic fingerprints of vesicles from prostatic fluid all feature in the review as rapidly maturing avenues. Emerging candidates such as annexin A3, the homeobox protein engrailed-2 (EN2), CRISP3, and the cholinergic peptide SLURP1 add to a growing catalog of tumor-specific molecules detectable in urine.

MicroRNAs and metabolomics round out the molecular picture. Circulating and urinary microRNAs—including miR-21, miR-145, miR-30b-3p, and miR-375—have shown the ability to distinguish prostate cancer from benign lesions, with novel detection platforms such as silver nanoparticle sensors pushing toward point-of-care measurement. Metabolomics takes aim at the tumor’s altered biochemistry: sarcosine in urine, lipid species in exosomes, and serum metabolite panels have all discriminated cancer from benign prostatic hyperplasia within the PSA gray zone, and a recent systematic review of pre-diagnostic untargeted metabolomics supports their prospective value. The biological rationale is sound, since prostate cancer undergoes profound metabolic reprogramming, and metabolites often change earlier than structural imaging can detect.

On the imaging side, the review catalogues technologies that go beyond conventional mpMRI. Biparametric and abbreviated MRI protocols promise wider access with comparable detection accuracy. Magnetic resonance elastography measures the physical stiffness of tissue—cancers are typically harder than benign tissue—and tomoelastography based on multifrequency MRE has outperformed mpMRI in head-to-head comparisons. Amide proton transfer-weighted imaging, a chemical exchange saturation transfer technique, probes tissue pH and protein content at the molecular level and has added value to PI-RADS v2.1 in detecting clinically significant disease. Micro-ultrasound, with resolution roughly three times finer than standard ultrasound, performed comparably to MRI in biopsy-naïve men and was tested head-to-head against MRI-guided biopsy in the OPTIMUM randomized trial. Most striking is PSMA PET/CT, which images the prostate-specific membrane antigen expressed on tumor cells; studies such as PRIMARY have shown its additive value to mpMRI triage, and [18F]DCFPyL PET/CT has reduced unnecessary biopsies in PI-RADS 3/4 patients—though benign prostatic hyperplasia-related false positives remain its acknowledged Achilles’ heel.

The review’s central thesis, however, is that no single test will win. Instead, the field is converging on multimodal integration. Risk calculators such as Stockholm3—which combines protein biomarkers, genetic variants, and clinical variables—have been validated in multiethnic cohorts and combined productively with MRI. PSA density and PHI density refine biopsy thresholds when layered onto PI-RADS scores, and combining the PRIMARY score with PSA density helps avoid unnecessary biopsies after negative mpMRI. Artificial intelligence is the connective tissue of this shift: deep learning models detect clinically significant cancer on MRI with performance approaching that of expert radiologists, as demonstrated in the international PI-CAI study published in Lancet Oncology, while multimodal AI systems that fuse clinical data, biomarkers, and imaging inputs have improved detection beyond any single modality. Radiomics—high-throughput extraction of quantitative image features—adds another layer, with machine learning models predicting malignancy even in equivocal PI-RADS 3 lesions.

The implications for patients are concrete. By sharpening the boundary between cancer and its benign mimics before biopsy, these tools could spare thousands of men annually from invasive procedures that carry morbidity and psychological cost, while directing biopsies more precisely toward those with clinically significant disease. The authors emphasize that this is a paradigm shift from single-parameter screening to multimodal, AI-assisted decision-making—personalized risk stratification built from blood, urine, and image data. Challenges remain, including validation across diverse populations, cost, and clinical implementation, but the trajectory is clear: the diagnostic gray zone that has frustrated urologists for three decades is finally being mapped, molecule by molecule and pixel by pixel, and the biopsy needle may soon arrive only where it is truly needed.

Subject of Research: Non-invasive pre-biopsy diagnostic strategies for discriminating prostate cancer from benign prostatic diseases

Article Title: Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population

Article References: Nie, Z., Zhu, T., Chen, Y., Zhang, W., & Wu, L. (2026). Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population. Medical Oncology, 43(11), Article 305. https://doi.org/10.1007/s12032-026-03424-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03424-1

Keywords: prostate cancer, PSA, liquid biopsy, multiparametric MRI, biomarkers, PI-RADS, artificial intelligence, PSMA PET, urine tests, risk stratification, prostate biopsy, metabolomics

The patient’s clinical journey began in January 2021, when he presented to an outpatient clinic with urinary frequency and progressive difficulty urinating. His initial serum total PSA measured 5.22 micrograms per liter, only modestly above the conventional 4 microgram-per-liter threshold that typically triggers concern. Magnetic resonance imaging revealed abnormal lesions in the peripheral zone of both sides of the prostate, and transrectal biopsy confirmed the suspicion: prostate adenocarcinoma with a Gleason score of 9 (4+5), one of the most aggressive grades assigned to this disease. The clinical stage was classified as T3aN0M0, indicating locally advanced disease that had not yet spread to lymph nodes or distant organs. Because of COVID-19 pandemic disruptions, radical surgery was postponed, and the patient instead began combined androgen blockade using bicalutamide and goserelin, a hormonal regimen designed to starve the cancer of the testosterone it craves.

Two years later, in February 2023, the patient was admitted with worsening urinary symptoms. Repeat MRI showed an enlarged prostate with lesions essentially unchanged from prior imaging, and a bone density scan detected no abnormalities. After a multidisciplinary team evaluation, he underwent laparoscopic radical prostatectomy in March 2023 without complications. Postoperative pathology reconfirmed the high-grade adenocarcinoma, and endocrine therapy with bicalutamide and goserelin continued. By June 2023, follow-up labs showed the total PSA had fallen to 0.86 micrograms per liter, while serum testosterone was undetectable. On paper, everything suggested the treatment was working: the primary tumor had been removed, hormonal therapy had chemically castrated the patient, and the biomarker that defines prostate cancer activity had collapsed to near-baseline levels.

Then, in August 2023, the picture shattered. The patient noticed a soybean-sized mass on his penis, accompanied by urinary frequency, urgency, painful urination, and five to six nighttime bathroom trips. Physical examination revealed a firm mass roughly three centimeters long within the penile corpus cavernosum, the spongy erectile tissue. Doppler ultrasonography identified a solid lesion measuring 26 by 16 by 11 millimeters in the left corpus cavernosum, suspicious for malignancy. MRI confirmed a solid mass with a high probability of metastatic tumor. Critically, his serum PSA at that moment was just 2.58 micrograms per liter, well within a range many clinicians would consider reassuring. He underwent resection of the penile lesion on August 24, 2023, and histopathology revealed poorly differentiated adenocarcinoma with intravascular tumor thrombus, evidence that cancer cells had already invaded blood vessels.

Immunohistochemical staining settled the question of origin. The tumor cells showed diffuse positive expression of androgen receptor, PSA, and P504s, also known as alpha-methylacyl-CoA racemase, a molecular fingerprint characteristic of prostate adenocarcinoma. The diagnosis was confirmed: penile metastasis from prostate cancer, an event with an estimated incidence of only 0.3 to 0.5 percent among prostate cancer patients. By October 2023, the disease had exploded. MRI detected multiple masses in both corpora cavernosa, the right ischium, and the left pubic ramus. Contrast-enhanced CT revealed scattered solid nodules in both lungs, a lesion in the right lobe of the thyroid, and multiple growing liver metastases, the largest measuring about 20 millimeters. His PSA had climbed to 13.39 micrograms per liter, and the team concluded he had relapsed with castration-resistant disease.

The authors place this case within a broader biological framework that may explain the paradox of metastasis without high PSA. In metastatic castration-resistant prostate cancer, low PSA levels often signal neuroendocrine differentiation, a process in which tumor cells undergo what researchers call lineage plasticity. Under the selective pressure of continuous hormonal therapy, adenocarcinoma cells accumulate genomic alterations such as RB1 and TP53 mutations and epigenomic changes including DNA methylation and EZH2 overexpression. The splicing regulator SRRM4 induces alternative splicing that produces a non-functional variant of the neuronal repressor REST, while upregulation of N-MYC, PEG10, and transcription factors like BRN2, SOX2, and SOX11 grants the cells stem-like and neuron-like properties. The cells shift toward a mesenchymal state, marked by elevated vimentin and SNAIL, suppressed androgen receptor signaling and its downstream genes including PSA, and increased neuroendocrine markers such as synaptophysin, chromogranin A, and neuron-specific enolase. The result is a tumor that proliferates aggressively but no longer manufactures the very protein clinicians use to track it.

The authors acknowledge an important limitation: their penile tumor specimen was not stained for neuroendocrine markers, so the evidence for this mechanism in the present case remains indirect. Still, the anatomical route of spread is clearer. Roughly 75 percent of metastatic penile cancer originates from adjacent genitourinary and pelvic organs, chiefly the bladder at 28.6 percent and the prostate at 27.9 percent. About 90 percent of secondary penile tumors disseminate through veins and lymphatics, with the remainder arriving via direct extension or iatrogenic implantation. In this patient, retrograde venous or lymphatic dissemination is the most likely mechanism, supported by the locally advanced initial stage, the intravascular tumor thrombus seen on histopathology, the corpus cavernosum involvement, and the rapid systemic dissemination that followed.

The clinical trajectory after the penile diagnosis was relentless. In November 2023, PSA reached 32.5 micrograms per liter and PET-CT identified extensive systemic metastases. By January 2024, the patient required a suprapubic cystostomy to manage urinary obstruction, and PSA had risen to 39.60 micrograms per liter. Treatment escalated through abiraterone and then enzalutamide, but by April 2024 PSA had surged to 253.01 micrograms per liter, and by late June it hit 577.47. Testosterone remained below detection, confirming that the cancer no longer depended on androgens. Laboratory values painted a picture of systemic decline: low potassium, low albumin, anemia with hemoglobin of 91 grams per liter, and elevated inflammatory markers including C-reactive protein at 71.38 milligrams per liter. Androgen deprivation therapy offered no benefit, so the team transitioned to metronomic therapy with opioid pain control. The patient died in August 2024, 43 months after his initial diagnosis and just 12 months after the penile metastasis was detected.

Survival statistics for this rare complication are grim across the literature. A 2006 review by Cherian and colleagues collected 372 cases of secondary penile tumors, 125 of them from prostate cancer, and found most patients died within a year of presentation. A 2023 update by Landen and colleagues added 72 new cases documented between 2006 and 2021, reporting a median cancer-specific survival of 14.3 months for prostate primaries. Approximately 41 percent of patients with prostate-derived penile metastasis die within six months of diagnosis, and those who develop malignant priapism fare even worse. Metastasis-directed therapies such as surgical excision, radiotherapy, and stereotactic body radiation can achieve favorable local PSA responses and relieve symptoms, but no study has demonstrated a meaningful overall survival benefit. For patients whose low PSA reflects neuroendocrine differentiation, current guidance suggests prioritizing chemotherapy with agents like docetaxel or cabazitaxel, platinum-based regimens, or emerging targeted therapies rather than continuing androgen deprivation alone.

The takeaway from this case is a call for diagnostic humility. The authors recommend that any patient presenting with penile complaints and a history of prostate malignancy should be suspected of harboring penile metastasis, even when bone disease appears controlled and PSA sits in the low range under hormonal therapy. Patients with high-grade, locally advanced prostate cancer and atypical features deserve heightened vigilance. Beyond conventional PSA testing, the report advocates complete physical examination, imaging with MRI or, preferably, gallium-68 PSMA PET/CT, the most sensitive modality for detecting prostate cancer metastasis, and additional serum biomarkers. Notably, this patient never received PSMA PET/CT because it was not part of routine workup at the treating institution, and the authors concede its absence may have allowed additional metastatic lesions to escape detection. As prostate cancer treatment extends survival for millions worldwide, this case stands as a vivid reminder that the disease can rewrite its own molecular identity, slipping beneath the biomarker radar precisely when clinicians feel most confident it has been defeated.

Subject of Research: Penile metastasis of prostate cancer occurring with low serum PSA levels

Article Title: Prostate cancer metastasis to the penis with low serum prostate specific antigen level: A case report

Article References: Wang, Z., Lai, Y., Wu, H., Zhang, J., Liang, H., & Wang, X. (2026). Prostate cancer metastasis to the penis with low serum prostate specific antigen level: A case report. Heliyon, 12(15), Article e45456. https://doi.org/10.1016/j.heliyon.2026.e45456

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45456

Keywords: prostate cancer, penile metastasis, PSA, castration-resistant prostate cancer, neuroendocrine differentiation, androgen deprivation therapy, PSMA PET/CT, case report, lineage plasticity, immunohistochemistry, Gleason score, Heliyon

The numbers tell a story of two very different diseases hiding under one diagnostic umbrella. Among the 607 patients classified as high-risk under the European Association of Urology classification, fluorine-18 sodium fluoride PET/CT detected bone metastases in 224 individuals, or 37 percent of the group. Yet among the 127 patients with unfavourable intermediate-risk disease and a tumour grade of ISUP grade group 3, exactly one patient, or 0.8 percent, turned out to have metastatic bone involvement. Follow-up data suggested one additional intermediate-risk patient may have harboured a metastasis that the initial scan missed, but even taking that possibility into account, the yield in this subgroup was vanishingly small.

The imaging technique itself is worth understanding, because its physics explains both its power and its pitfalls. After intravenous injection, the fluoride ion travels through the bloodstream in proportion to regional blood flow and exchanges with hydroxyl ions in hydroxyapatite, the mineral scaffold of bone, to form fluoroapatite. This means the signal captured by the PET camera reflects two biological processes at once: bone perfusion and osteoblastic activity, the cellular machinery that lays down new bone. Bone metastases typically provoke exactly this kind of remodelling, which is why they light up brightly on the scan. The catch is that benign conditions, from arthritis to healing fractures, provoke the same response, so interpretation demands experienced readers who can distinguish malignant patterns from incidental noise.

In this study, ten nuclear medicine specialists who collectively analyse more than 3,000 scans per year interpreted the images. Only 24 of the 734 scans, roughly 3 percent, were classified as equivocal, and two experts blinded to the original reports reanalysed each of those cases to reach a consensus diagnosis, concluding that 20 of the 24 patients did not have bone metastases. That low equivocal rate stands in sharp contrast to the older technology that shaped current guidelines. Planar bone scintigraphy using technetium-99m labelled diphosphonates, the workhorse of previous decades, produces far more ambiguous results. In one retrospective study of 853 patients cited by the Danish team, 16 percent of scans were equivocal; in another of 703 patients, the figure reached 42 percent, forcing a cascade of additional imaging.

To establish how trustworthy the PET findings actually were, the researchers constructed a rigorous reference standard. A nuclear medicine specialist reviewed all available follow-up imaging alongside clinical records, and when the picture remained unclear, a urologic specialist weighed the full clinical data set. Evidence supporting metastatic disease ranged from histologic verification and confirmatory MRI or PSMA PET/CT findings down to patterns of increasing fluoride uptake or newly emerging lesions consistent with treatment failure. Evidence against included undetectable prostate-specific antigen after radical prostatectomy, negative complementary imaging, and consistently negative follow-up scans paired with stable or falling PSA in the absence of systemic therapy. For the 689 patients, 94 percent of the cohort, in whom this process yielded a conclusive verdict, fluorine-18 sodium fluoride PET/CT achieved a sensitivity of 0.90 and a specificity of 0.99, figures the authors describe as consistent with the best previous estimates.

Within the high-risk group, the analysis confirmed what clinicians have long suspected about the biology of prostate cancer’s spread to bone. Higher PSA levels, more advanced clinical tumour stage, and higher ISUP grade groups each carried independently increasing odds of metastasis in multivariate logistic regression, with the three variables adjusted for potential confounding. This dose-response relationship across the classic risk markers reinforces that bone imaging is genuinely informative precisely where the disease is most aggressive. The problem, the authors argue, is that guidelines extrapolated from planar bone scintigraphy-era evidence have never been systematically revalidated for modern scanners, and the diagnostic pathway itself has shifted underneath them, with MRI-targeted biopsies now upgrading many tumours into higher grade categories and shifting patients between risk groups.

The single intermediate-risk patient with a confirmed metastasis illustrates how subtle these cases can be. The scan revealed a single sclerotic lesion in the right pubic bone with avid fluoride uptake, subsequently confirmed by gallium-68 PSMA-11 PET/CT. The patient underwent radical prostatectomy as part of a clinical trial for oligometastatic disease, and histopathology of the removed prostate showed grade group 5 disease, a reminder that grade can be underestimated before the whole gland is examined. The second intermediate-risk patient, whose initial scan showed no lesions, received curative radiotherapy and 17 months of medical castration before treatment was stopped due to side effects; three and a half years later, a follow-up sodium fluoride PET/CT revealed a suspicious lesion in the left pubic bone, and the original scan was retrospectively classified as false-negative.

How do these results square with the newer contender in the field, PSMA PET/CT? A retrospective multicenter study of 396 intermediate-risk patients with grade group 3 disease, examined with four different PSMA radioligands, found bone metastases in 4 percent overall, but the rate varied dramatically by tracer: 21 percent with fluorine-18 PSMA-1007 against just 3 percent with gallium-68 labelled agents. That discrepancy matters because fluorine-18 PSMA-1007 is known to produce uptake in non-specific bone lesions, meaning some of those positives were likely false. A separate study of 1,253 consecutive men staged with gallium-68 PSMA-11 PET/CT detected bone metastases in only 3 percent of 638 intermediate-risk patients. Both figures align closely with the Danish sodium fluoride results, and they carry a practical warning: when the pretest probability of bone involvement is this low, isolated PSMA-avid bone lesions should be interpreted with considerable caution, since non-specific uptake may account for a substantial share of positive findings.

The authors are candid about the limitations that temper their conclusions. The retrospective, single-center design introduces potential selection bias and limits control over imaging indications and follow-up procedures. The reference standard relied on follow-up rather than histology in most cases, leaving room for misclassification, and systemic treatment started after the index scan may have masked metastases that would otherwise have declared themselves. The sensitivity estimate in the intermediate-risk subgroup rested on just two positive patients, making it statistically imprecise. Biopsy technique also varied across the cohort, with some men receiving systematic ultrasound-guided biopsies and others MRI-targeted sampling from March 2019 onward, a heterogeneity that may have influenced ISUP grading and therefore risk stratification itself.

Even with those caveats, the central message is hard to escape. Fluorine-18 sodium fluoride PET/CT performs superbly where it matters most, catching bone metastases in more than a third of high-risk patients with sensitivity and specificity approaching the ceiling of what imaging can achieve. But for men with unfavourable intermediate-risk disease and grade group 3 tumours, the scan found metastases in one patient out of 127, and the authors conclude that routine use in this subgroup appears to have limited clinical value. As hospitals worldwide weigh the cost, radiation exposure, and logistical burden of staging imaging against genuine benefit, this study offers a data-driven argument for narrowing the net, reserving advanced bone imaging for the patients in whom the disease is truly likely to have already reached the skeleton.

Subject of Research: Diagnostic accuracy of fluorine-18 sodium fluoride PET/CT for detecting bone metastases in newly diagnosed prostate cancer

Article Title: Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer

Article References: Madsen, C., Zacho, H. D., Bisbjerg, R., Fuglø, D., & Østergren, P. B. (2026). Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08148-y

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08148-y

Keywords: prostate cancer, bone metastases, NaF PET/CT, PSMA PET/CT, bone scintigraphy, diagnostic accuracy, intermediate-risk, ISUP grade group, EAU guidelines, PSA, nuclear medicine, staging

The report follows Larry Hardesty, a 76-year-old patient who is also a co-author of the paper and who experienced three distinct recurrences of prostate cancer after undergoing prostatectomy. Rather than following a single fixed treatment plan, his care evolved each time the disease reappeared in a new location, guided by a multidisciplinary team spanning urology, radiation oncology, medical oncology, nuclear medicine and advanced imaging. After his third recurrence, treated with a combination of a PSMA-targeted radioligand therapy and stereotactic body radiation therapy, his PSA became undetectable and follow-up imaging showed no evidence of active disease. His PSA has remained undetectable through 10.5 years after his original surgery, a remarkable outcome for a cancer that had repeatedly outmaneuvered conventional approaches.

Dr. Amar Kishan, the study’s first author, professor and executive vice chair of radiation oncology at the David Geffen School of Medicine at UCLA and co-director of the cancer molecular imaging, nanotechnology and theranostics program at the UCLA Health Jonsson Comprehensive Cancer Center, emphasized that recurrent prostate cancer is not a single clinical entity. “Recurrent prostate cancer can look very different from one patient to another and even within the same patient over time,” Kishan said. “This case shows why multidisciplinary care is so important. We have to bring together what we know from imaging, radiation, systemic therapy and clinical trials and continually reassess the best approach as the disease changes.” That philosophy, he argued, is what allowed Hardesty’s team to pivot effectively each time the cancer shifted its behavior or its anatomical address.

The technical backbone of the case is prostate-specific membrane antigen, or PSMA, imaging. PSMA is a protein abundantly expressed on the surface of most prostate cancer cells, and radiotracers designed to bind it allow positron emission tomography, or PET, combined with computed tomography, to reveal deposits of disease far smaller than conventional imaging can resolve. In Hardesty’s case, his PSA first became detectable roughly three years after surgery, and a PSMA PET/CT scan identified a small recurrence in the prostate bed, the region where the gland once sat, along with several cancer-containing lymph nodes. Armed with that anatomical precision, his physicians delivered stereotactic body radiation therapy, or SBRT, a technique that concentrates ablative doses of radiation in a small number of treatments, sculpting high-intensity beams around individual tumors while sparing surrounding healthy tissue.

Yet the cancer’s return in lymph nodes farther up the abdomen exposed a fundamental limitation that no imaging technology has yet overcome. Doctors can only treat tumors they can see, and microscopic seeds of disease may already be spreading elsewhere in the body long before any scan can detect them. This gap between macroscopic and microscopic disease is the central dilemma of recurrent prostate cancer, and it is precisely the problem that the UCLA team’s sequential clinical trials were designed to probe. When Hardesty’s cancer returned a second time, he enrolled in the SATURN clinical trial, receiving SBRT to the visible lesions along with six months of intensive hormone therapy, an androgen-deprivation approach that starves prostate cancer cells of the testosterone they depend on. His PSA fell, but it eventually began to rise again, and a subsequent PSMA scan revealed two new cancerous lymph nodes and another recurrence in the prostate bed.

The third recurrence prompted enrollment in the phase 2 LUNAR trial and a decisive shift in strategy: two cycles of 177Lu-PNT2002, a radioligand therapy that couples a beta-emitting radioactive isotope of lutetium-177 to a molecule that homes in on PSMA-positive cancer cells throughout the body. Unlike external beam radiation, which must be aimed at specific targets, radioligand therapy travels through the bloodstream, delivering radiation directly to prostate cancer cells wherever they express the PSMA protein, including deposits too small to appear on any scan. Hardesty then received SBRT as well. The combination proved effective. His PSA eventually became undetectable, PSMA scans performed at 12 and 24 months showed no evidence of active disease, and his PSA has remained undetectable more than a decade after his prostatectomy.

Hardesty’s own perspective, included in the report through his role as co-author, adds a human dimension to the clinical narrative. “I have felt fortunate to have access to so many trials, and even though two of them didn’t work, I feel like I received cutting-edge care,” he said. “And this last one seems to have done the trick.” His candor about the two unsuccessful trials is itself instructive. In precision oncology, negative results within an individual patient’s course are not failures of the enterprise but data points that redirect strategy, and his willingness to participate sequentially in three investigator-initiated UCLA trials meant that each recurrence was met with an emerging, evidence-generating approach rather than a default option.

The case also captures a paradox of modern prostate cancer medicine: every advance that expands the therapeutic arsenal simultaneously complicates decision-making. PSMA imaging can now detect recurrent disease at volumes once considered undetectable, raising questions about when and how aggressively to intervene. SBRT can sterilize individual oligometastatic lesions with remarkable precision. PSMA-targeted radioligand therapies, once reserved for advanced metastatic disease, are moving earlier in the treatment course through trials like LUNAR. Hormone therapy can be intensified, shortened, or combined in ways that balance efficacy against side effects. Deciding among these options requires weighing the location of the cancer, the patient’s prior treatments, the biology suggested by the pattern of recurrence and the best available evidence, a synthesis that no single specialist can provide alone. It is this integration, the researchers argue, that defines contemporary multidisciplinary care.

“This isn’t a story about one treatment being the answer,” Kishan said. “It’s about bringing together different areas of expertise and using the evidence available at each point in a patient’s journey to make the best treatment decision we can. As the cancer changes, our approach has to change with it.” The researchers note that ongoing randomized clinical trials will help resolve several open questions highlighted by the case: the optimal timing of hormone therapy, which patients derive the greatest benefit from metastasis-directed radiation, and how PSMA-targeted radioligand therapy can best be woven together with other treatment modalities. Until those answers arrive, carefully documented cases like this one serve as proof of concept that adaptive, trial-driven, team-based care can hold recurrent disease at bay for years.

The study’s senior author is Matthew Rettig, professor of urology and medical director of the prostate cancer program at the David Geffen School of Medicine at UCLA. Other authors, all from UCLA, are Yulia Zekster, Adam Singer, Kekoa Taparra, Luca Valle, Michael Steinberg, Nicholas Nickols, Robert Reiter, Johannes Czernin, Jeremie Calais and John K. Lee. For patients facing a rising PSA after surgery, the report offers both a caution and a source of hope: recurrence is not a single event but a process, and with advanced imaging to find what can be seen, radioligand therapy to reach what cannot, and clinical trials to keep pushing the frontier, the process can be met, again and again, with a plan.

Subject of Research: Multidisciplinary management of recurrent prostate cancer using PSMA imaging, stereotactic radiation and radioligand therapy

Article Title: Case report highlights multidisciplinary approach to recurrent prostate cancer

Article References: Case report highlights multidisciplinary approach to recurrent prostate cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, PSMA imaging, radioligand therapy, stereotactic body radiation therapy, clinical trials, recurrence, PSA, hormone therapy, multidisciplinary care, UCLA Health, 177Lu-PNT2002, oncology

The first of the headline findings confronts a blind spot that has persisted in radiation therapy quality assurance for decades. Stereotactic radiosurgery, or SRS, is a technique that delivers very high doses of radiation to small intracranial targets in one or just a few fractions, and its therapeutic window depends entirely on accuracy: the dose must conform tightly to the target while sparing surrounding healthy brain tissue. Historically, quality assurance audits have concentrated on the machines themselves, verifying that linear accelerators and other platforms deliver the dose they are programmed to deliver with precision and accuracy. What those audits did not measure was the quality of the radiation plan that clinicians feed into the machine, even though planning decisions can vary enormously between practitioners and institutions.

To close that gap, a team from MD Anderson’s Image and Radiation Oncology Core, or IROC, analyzed more than 800 radiation treatment plans contributed by over 650 institutions between 2013 and 2025. Crucially, every plan was designed for the same target inside a standardized head phantom, a physical model engineered to measure radiation delivery under controlled and comparable conditions. This design allowed the researchers to isolate the contribution of human and institutional planning choices from the intrinsic capabilities of different treatment hardware. The results were striking: across treatment platforms, the volume of healthy brain receiving a high dose differed by nearly a factor of five. While the physical limits of each machine accounted for part of that spread, the study found that on standard linear accelerators, the planner’s decisions explained more of the variability than the equipment itself. The single most consequential choice was how tightly the radiation field was shaped around the target.

Lian Duan, a Ph.D. candidate in Radiation Physics who presented the findings, emphasized that the implications extend well beyond the audit itself. “The same plan on different machines does not mean the same dose to healthy brain,” Duan said. “Clinics should benchmark against their own equipment and treat that benchmark as a starting point. Careful planning on the same hardware can still improve a plan substantially.” In other words, two clinics operating identical accelerators could be delivering dramatically different doses to their patients’ healthy brain tissue simply because of how their planners conform the field, a variable that no machine-focused quality assurance program would ever capture. Duan conducts the work with Stephen Kry, Ph.D., within IROC, one of only four centers in the United States funded by the National Cancer Institute, part of the National Institutes of Health, to verify and maintain quality standards for radiation therapy across cancer clinical trials. That mandate gives the group a national vantage point on how consistently, or inconsistently, radiation plans are actually built.

The practical takeaway for the field is a call to institutional self-examination. Rather than assuming that possession of modern hardware guarantees optimal plan quality, the MD Anderson team argues that clinics should measure their own plan performance against benchmarks established on their specific equipment, and then treat continuous planning improvement as an ongoing quality objective. Because SRS is used to treat brain metastases, benign brain tumors, and other intracranial lesions where normal tissue dose directly influences the risk of radiation necrosis and cognitive effects, a nearly fivefold difference in high-dose exposure to healthy brain represents a clinically meaningful gap, not a statistical curiosity. The study reframes plan quality as a modifiable variable under the control of every clinic, independent of its capital equipment.

The second headline study turns from physics to biology, and to a clinical trial whose results changed standard practice. NRG/RTOG 9601 was a landmark phase 3 prostate cancer study demonstrating that adding anti-androgen hormone therapy to salvage radiation therapy improved outcomes for patients whose prostate-specific antigen rose after radical prostatectomy, signaling that the cancer had returned. The trial’s results reshaped clinical guidelines and made combined hormone therapy plus salvage radiation a common recommendation. But anti-androgen therapy carries significant side effects, and at the time the initial results were published, clinicians had no reliable method for identifying which individual patients would actually benefit from the added treatment. Subsequent research showed that measuring prostate-specific antigen, or PSA, a protein produced by prostate cells, could help guide decisions, yet even with PSA testing, estimating how aggressive a particular patient’s recurrence truly is remains a persistent challenge.

Krishnan Patel, M.D., associate professor of Radiation Oncology at MD Anderson, led an effort to answer that question with modern tools. His team applied a contemporary genomic classifier, a test that evaluates genetic material within the tumor to predict its likely behavior, to archived tumor samples from the landmark trial. The genomic test successfully separated patients into risk groups with markedly different long-term outcomes. Fifteen years after treatment, 75 percent of patients in the low-risk group were still alive, compared with only 25 percent of those in the very high-risk group. That degree of separation, derived from samples collected roughly two decades ago, illustrates how molecular diagnostics can extract clinically actionable prognostic information from historical trial cohorts and validate a modern assay against the gold standard of a completed, practice-changing phase 3 study with long-term survival follow-up.

Beyond prognosis, the analysis carries direct implications for treatment personalization. The study suggests that the genomic classifier can complement, rather than replace, standard blood tests such as PSA. Under current patterns of care, many physicians recommend hormone therapy for men with high pre-radiation PSA levels and withhold it from those with low values. The new findings indicate that a distinct subgroup of patients with low pre-radiation PSA levels but aggressive biological features on genomic testing may nonetheless benefit from hormone therapy, while others with apparently elevated risk by conventional measures may be spared its toxicities. “The ability to apply a modern genomic test to samples from a clinical trial conducted nearly two decades ago is incredibly valuable,” Patel said. “These findings are helping us continue to personalize treatment recommendations, allowing some patients who are unlikely to benefit from hormone therapy avoid its side effects, while giving clinicians greater confidence in identifying those who are most likely to benefit.”

Taken together, the two presentations illustrate the dual trajectory of contemporary radiation oncology: one line of research perfecting the physical delivery of treatment, the other refining the biological selection of which treatments each patient should receive. The SRS planning study shows that substantial gains in safety may be achievable without new machines, purely through better planning practice and systematic benchmarking. The prostate cancer genomic analysis shows that molecular profiling, validated against long-term outcomes from a definitive trial, can move hormone therapy decisions from population-level defaults toward individualized prescriptions. Both studies underscore a theme that runs throughout MD Anderson’s nearly 70 abstracts at this year’s meeting: precision in radiation oncology is as much about decisions and data as it is about dose.

The meeting also serves as an occasion to recognize individual achievement within the department. Bruce Minsky, M.D., professor emeritus of Radiation Oncology at MD Anderson, will receive ASTRO’s Gold Medal, the society’s highest honor. Chelsea Pinnix, M.D., Ph.D., professor of Radiation Oncology, has been named an ASTRO Fellow, and Clifton Fuller, M.D., Ph.D., professor of Radiation Oncology, will receive the society’s 2026 Mentorship Award for his role in developing the next generation of physician-scientists in the field. Additional information on all MD Anderson presentations at the ASTRO Annual Meeting is available through the institution’s dedicated meeting hub, and the full abstract catalog is published by ASTRO as part of the official scientific program.

Subject of Research: Quality assurance in stereotactic radiosurgery planning and genomic prediction of prostate cancer outcomes in salvage radiotherapy

Article Title: ASTRO: UT MD Anderson highlights advances in radiation oncology

Article References: ASTRO: UT MD Anderson highlights advances in radiation oncology. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: radiation oncology, stereotactic radiosurgery, quality assurance, medical physics, prostate cancer, genomic classifier, NRG/RTOG 9601, salvage radiotherapy, androgen deprivation therapy, ASTRO 2026, MD Anderson Cancer Center, PSA